The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1495
QuilliChew ER - Extended-Release Chewable Methylphenidate Tablets
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a once-daily, extended-release chewable tablet formulation of methylphenidate (QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first long-acting chewable formulation of the drug to be marketed in the US. Immediate-release chewable methylphenidate tablets (Methylin, and generics) have been available since 2003.1

METHYLPHENIDATE — Short-acting methylphenidate formulations are effective for treatment of ADHD, but their 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing. Long-acting methylphenidate preparations have therefore become the mainstay of clinical practice. Most long-acting formulations are available only as tablets or capsules that many children find difficult to swallow. Some capsules can be opened and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: QuilliChew ER - Extended-Release Chewable Methylphenidate Tablets
Article code: 1495b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian